Phathom Pharmaceuticals (PHAT) PT Raised to $12 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Phathom Pharmaceuticals Inc. (PHAT) spreader active in August 10 and November 10 calls
August 8, 2024 2:53 PM EDTPhathom Pharmaceuticals Inc. (NASDAQ: PHAT) 30-day option implied volatility is at 82; compared to its 52-week range of 55 to 180 with a focus on August 10 and November 10 call spread.
... MorePhathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 7c
August 8, 2024 8:05 AM EDTPhathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of ($1.25), $0.07 better than the analyst estimate of ($1.32). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $5.68 million.
For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.
... More